Jacob Bell

Shares in AbbVie slumped by double digits Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two Phase 2 trials.

Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.

Jacob Bell 3 min read In This Article This story was originally published on BioPharma Dive . To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter

Emraclidine, a promising psychiatric medicine AbbVie acquired by buying Cerevel Therapeutics last year, didn't outperform placebo in two Phase 2 trial tests.

Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in people living with the nerve-destroying disorder.

Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in people living with the nerve-destroying disorder.

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke with BioPharma Dive about how the company came together.

Negative results from a Huntington’s trial add to a difficult year for Sage, which last month decided to overhaul its research, reconfigure its executive team and lay off a third of its staff.

In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like Duchenne muscular dystrophy and myotonic dystrophy type 1.